



China and Europe towards
Cooperation in Personalised Medicine

SINO-EU PerMed: The article “Sino-European science and technology collaboration on personalized medicine: overview, trends and future perspectives” is now published on Future Medicine

The International Project SINO-EU PerMed started in 2020 to reinforce collaboration between Europe and China on a vital topic for fight diseases, improve public health and keep health systems sustainable

The first 12 months of the European project Sino-Eu PerMed have been dedicated to the scientific, technological and funding programmes mapping in the field of Personalised Medicine, which poses the basis to understand the current level of collaboration, analyse its main barriers and devise a bilateral strategy to reinforce collaboration at multiple levels

Fondazione Toscana Life Sciences (TLS), together with the the German Aerospace Center (Deutsches Zentrum für Luft- und Raumfahrt, DLR), the Innovation Fund Denmark (IFD), the Health Research Board (HRB), the Jiangsu Centre of International Technology Transfer (JITTC) and the Guangzhou Institutes of Biomedicine and Health (GIBH), has discussed the relevant outcomes of this mapping activity within a scientific paper titles "[Sino-European science and technology collaboration on personalized medicine: overview, trends and future perspectives](#)", which has been published on peer reviewed journal Future Medicine on June 1st, 2021.

The paper and the mapping aimed at assessing the status of the recent collaborations between Europe and China on Personalised Medicine-related science, technology and funded research by analysing available scientific literature, patents and funding programs.

Results show that Personalised Medicine is a scientific and industrial priority in both geographical areas, but current levels of collaboration are not yet optimal. This suggests that cooperation between researchers, innovators, industries, regulators, funding agencies and healthcare systems should be increased and a forum to exchange best practices, define common guidelines for Personalised Medicine implementation and promote public-private partnerships should be promoted.

Currently the project partners are developing a strategic plan in order to reinforce innovation capacity of the two Regions and to reinforce the dialogue between ICPeMed and the Chinese stakeholders.

In the last phase of the project the consortium will promote multilevel collaboration (academic, industrial and business) through the organisation of ad-hoc events both in China and Europe.

If you want to get more information on the publication and on the Sino-EU PerMed project please [register](#) to the Sino-EU PerMed workshop taking place on the 1 July 10:00-12:00 CEST.